Lates News

According to the AI news of Each Economy, Huayuan Securities released a research report on September 3, giving Fangsheng Pharmaceutical (603998.SH) a buy rating. The main reasons for the rating include: 1) The performance of the first half of 25H1 meets expectations, continuing to focus on the pharmaceutical industry as the main business; 2) Innovative Chinese medicine is gradually becoming a new profit growth point for the company. (Daily Economic News)